{
    "clinical_study": {
        "@rank": "137766", 
        "arm_group": [
            {
                "arm_group_label": "Statin", 
                "arm_group_type": "Experimental", 
                "description": "Atorvastatin 10 mg every day for one year"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year."
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized controlled trial of statin intervention in dyslipidemic obese teenagers.  Primary\n      outcome is intima media thickness before and after intervention."
        }, 
        "brief_title": "Intima Media Thickness Regression in Dyslipidemic Teenagers", 
        "completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Obesity", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Dyslipidemias"
            ]
        }, 
        "detailed_description": {
            "textblock": "Obese teenagers with abnormal lipid profiles were randomized to either low dose statin or\n      placebo and had their carotid intima media thickness compared before and after intervention."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Obesity\n\n          -  Abnormal Triglyceride levels (>1.7mmol/L).\n\n          -  Abnormal HDL-C levels (1.0mmol/L)\n\n        Exclusion Criteria:\n\n          -  Abnormal thyroid unfction (not treated)\n\n          -  Diabetes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768481", 
            "org_study_id": "HMR"
        }, 
        "intervention": [
            {
                "arm_group_label": "Statin", 
                "description": "10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Statin", 
                    "Lipitor"
                ]
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "description": "placebo controlled arm receives similarly looking placebo.", 
                "intervention_name": "sugar pill", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Dyslipidemia", 
            "Cholesterol", 
            "Intima media thickness"
        ], 
        "lastchanged_date": "January 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montr\u00e9al", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H1T 2M4"
                }, 
                "name": "H\u00f4pital Maisonneuve-Rosemont"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intervention pr\u00e9coce Sur Les Indices d'ath\u00e9rog\u00e9n\u00e8se Des Adolescents \u00e0 Risque", 
        "other_outcome": [
            {
                "description": "Complete lipid profile were recorded at baseline , 6 months and 12 months after intervention.", 
                "measure": "Lipid profile", 
                "safety_issue": "No", 
                "time_frame": "6  months"
            }, 
            {
                "description": "Lipid profile measured at end of study", 
                "measure": "lipid profile", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "BMI neasured at baseline and at end of study", 
                "measure": "BMI", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "ALT/AST done at 3, 6, 9 and 12 months", 
                "measure": "liver functions", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "ALT/AST done at 3, 6, 9, and 12 months", 
                "measure": "liver functions", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "ALT/AST done at 3, 6, 9, and 12 months", 
                "measure": "liver functions", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "ALT/AST done at 3, 6, 9, and 12 months", 
                "measure": "liver functions", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "CK done at 3 , 6, 9 and 12 months", 
                "measure": "creatinine kinase", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "CK done at 3 , 6, 9 and 12 months", 
                "measure": "creatinine kinase", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "CK done at 3 , 6, 9 and 12 months", 
                "measure": "creatinine kinase", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "CK done at 3 , 6, 9 and 12 months", 
                "measure": "creatinine kinase", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "overall_official": {
            "affiliation": "Hopital Maisonneuve-Rosemont, UMontreal", 
            "last_name": "Laurent Legault, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Carotid Intima media thickness measured at baseline and after 12 months in 2 arms (placebo and statin)", 
            "measure": "carotid intima media thickness", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768481"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 de Montr\u00e9al", 
            "investigator_full_name": "Laurent Legault", 
            "investigator_title": "associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "weight, height and BMI recorded before and after intervention", 
            "measure": "weight", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Universit\u00e9 de Montr\u00e9al", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Universit\u00e9 de Montr\u00e9al", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2004", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}